Smartleaf Asset Management’s Rani Therapeutics RANI Stock Holding History

Smartleaf Asset Management’s Portfolio RANI Stock Details RANI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$800	Buy	+1,000	New	+$798	﹤0.01%	3259

Other funds holding RANI

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Kestra Private Wealth Services Austin, Texas $9.37B AUM 22.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

CWA Asset Management Group Naples, Florida $3.39B AUM 25.16% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Luther King Capital Management (LKCM) Fort Worth, Texas $24.3B AUM 19.37% 1-Year Est. Return

Well Done LLC Holland, Michigan $732M AUM 14.62% 1-Year Est. Return

MOTCO San Antonio, Texas $1.22B AUM 20.31% 1-Year Est. Return

Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return

Zurich Cantonal Bank Zurich, Switzerland $53.5B AUM 32.01% 1-Year Est. Return

Smartleaf Asset Management's RANI Position: Q3 2026 in Review

Smartleaf Asset Management opened a new position in Rani Therapeutics (RANI) in Q3 2026: 1,000 shares worth $800. The stake represents ﹤0.01% of the portfolio and ranks #3259 among its holdings.

27 funds tracked by Wall St. Rank hold RANI as of Q3 2026.

Smartleaf Asset Management held 1,000 shares of Rani Therapeutics worth $800 as of Q3 2026.
Rani Therapeutics was a new Smartleaf Asset Management position in Q3 2026.
Rani Therapeutics made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q3 2026, its #3259 holding.
27 funds tracked by Wall St. Rank held Rani Therapeutics as of Q3 2026.

Based on Smartleaf Asset Management's 13F filing for Q3 2026, filed 10 Nov 2026.